echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Is the life and death line of small and medium-sized pharmaceutical companies incorporated or broken through?

    Is the life and death line of small and medium-sized pharmaceutical companies incorporated or broken through?

    • Last Update: 2013-07-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2013-07-16 source: what about the enterprises that can't get the basic drugs through the new express? Is it driven to death by the fierce competition in the retail market, waiting to be acquired, or is it necessary to fight for a bloody way to increase market share? These two choices have puzzled thousands of small and medium-sized pharmaceutical enterprises in China recently A number of people in the pharmaceutical industry said in an interview with reporters yesterday that basic drugs are the world of large enterprises If small and medium-sized pharmaceutical enterprises want to open up a day beyond basic drugs, they need precision marketing to do the market, or they will face annexation In fact, in recent years, small and medium-sized pharmaceutical enterprises have been merged and acquired, such as China Resources 39 "incorporated" Linqing Huawei Pharmaceutical Co., Ltd., Shanghai Pharmaceutical Co., Ltd acquired Dongying Pharmaceutical Co., Ltd with a holding of RMB 615 million, Shanghai Laishi "swallowed" Banghe Pharmaceutical Co., Ltd., and Renhe Pharmaceutical Co., Ltd also obtained 100% equity of Dongke Pharmaceutical Co., Ltd In the first half of 2013, the number of pharmaceutical M & a ranked first in the whole industry According to the data from Qingke Research Center, in the first half of 2013, the biotechnology / medical health industry ranked first in M & A activity in all industries with 22 cases, accounting for 13.5% of the total Among the M & A cases completed in June, biotechnology / healthcare industry ranked first in the number of M & A, with 13 cases completed, accounting for 20.3% of the total cases In addition to the tide of M & A, M & A is also the direction of policy The Ministry of industry and information technology has long formulated the 12th Five Year Plan for the development of pharmaceutical industry, which clearly indicates that the concentration of pharmaceutical industry will be greatly increased By 2015, there are more than 5 enterprises with sales revenue of more than 50 billion yuan, and more than 100 enterprises with sales revenue of more than 10 billion yuan The sales revenue of the top 100 enterprises accounts for more than 50% of the whole industry At the same time, the production of essential drugs must also be concentrated to the dominant enterprises, with the top 20 enterprises in the sales of major varieties accounting for more than 80% of the market share This means that resources will move closer to large enterprises However, according to Jiang Guangce, a German medical fund, the concentration of the top 100 domestic pharmaceutical enterprises is only 41% This means that large-scale M & A will continue in the future In addition, according to incomplete statistics, among the 4500 pharmaceutical enterprises in China, only a few have sales revenue of more than 10 billion yuan From the threshold of the top 100 pharmaceutical enterprises in the past years, only the sales revenue of more than 1 billion yuan will be listed in 2011, which means that the scale of more than 4000 enterprises is less than 1 billion yuan, while the industry says that most pharmaceutical enterprises have sales revenue of 1 billion yuan Between 100 million yuan and 300 million yuan The fate of these small and medium-sized pharmaceutical enterprises in the future is either to become stronger or to be acquired Industry refers to simple report consolidation not a long-term plan At the time of the surge of M & A, an insider who didn't want to be named said that the policy and policy of the state's key support for large pharmaceutical enterprises also brought about a strange phenomenon in the industry: in order to achieve the scale of policy support, many pharmaceutical enterprises blindly carry out merger and acquisition, but in fact, they just simply combine the financial statements, and the production lines and business relations have not been effectively integrated, resulting in A lot of repeated development and waste of resources In such a scenario, many pharmaceutical companies have changed their strategies, strengthened themselves, and entered the OTC market However, the OTC market is not easy now Xiao Wenfeng, general manager of effective marketing project, pointed out that at present, OTC teams in the industry are facing a contradiction, that is, there is an irreconcilable contradiction between the requirements of OTC for fine brand operation and the extensive management of the enterprise itself With the rise of new media, the advertising revenue is also getting lower and lower In addition, in recent years, all industries are facing increasing human cost, OTC Enterprises can be said to have entered the cold winter period So, how can small and medium-sized enterprises that have not entered the drug base catalogue not only be merged, but also live well in the retail market? Kong Zhi, founder of the concept of effective marketing, said that the introduction of external brain, or a higher price ratio than the self built marketing team of small and medium-sized pharmaceutical enterprises, is to outsource marketing to a professional team to operate, and small and medium-sized enterprises are in charge of drug production and quality, so that professional people can do professional things It is understood that the OTC actual effect Corps under the command of Kong Zhi is playing such a role as an outsider, and is building a top domestic OTC marketing team to directly let the enterprise's marketing plan be implemented.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.